Eliezer Jesus de Lacerda Barreiro

List of Publications by Year
in descending order

278 papers	9,975 citations	53794 45 h-index	45317 90 g-index

294 all docs	294 docs citations	294 times ranked	12179 citing authors

#	Article	IF	Citations
1	LASSBio-596: a New Pre-clinical Candidate for Rheumatoid Arthritis?. Inflammation, 2022, 45, 528-543.	3.8	0
2	Comparative chemical and biological hydrolytic stability of homologous esters and isosteres. Journal of Enzyme Inhibition and Medicinal Chemistry, 2022, 37, 718-727.	5.2	6
3	Pre-clinical evaluation of LASSBio-1491: From in vitro pharmacokinetic study to in vivo leishmanicidal activity. PLoS ONE, 2022, 17, e0269447.	2.5	3
4	Identification of LASSBio-1945 as an inhibitor of SARS-CoV-2 main protease (M^{PRO}) through in silico screening supported by molecular docking and a fragment-based pharmacophore model. RSC Medicinal Chemistry, 2021, 12, 110-119.	3.9	16
5	Design and Synthesis In Silico Drug-like Prediction and Pharmacological Evaluation of Cyclopolymethylenic Homologous of LASSBio-1514. Molecules, 2021, 26, 4828.	3.8	0
6	Effect of Sâ€“Se Bioisosteric Exchange on Affinity and Intrinsic Efficacy of Novel N-acylhydrazone Derivatives at the Adenosine A2A Receptor. Molecules, 2021, 26, 7364.	3.8	0
7	Î²-lactam antibiotics: An overview from a medicinal chemistry perspective. European Journal of Medicinal Chemistry, 2020, 208, 112829.	5.5	227
8	Novel VEGFRâ€2 inhibitors with an Nâ€acylhydrazone scaffold. Archiv Der Pharmazie, 2020, 353, e2000130.	4.1	3
9	New Benzofuran N-Acylhydrazone Reduces Cardiovascular Dysfunction in Obese Rats by Blocking TNF-Alpha Synthesis . Drug Design, Development and Therapy, 2020, Volume 14, 3337-3350.	4.3	4
10	In Vitro, In Vivo and In Silico Effectiveness of LASSBio-1386, an N-Acyl Hydrazone Derivative Phosphodiesterase-4 Inhibitor, Against Leishmania amazonensis. Frontiers in Pharmacology, 2020, 11, 590544.	3.5	6
11	Bioisosteric Replacement of Arylamide-Linked Spine Residues with N-Acylhydrazones and Selenophenes as a Design Strategy to Novel Dibenzosuberone Derivatives as Type I 1/2 p38Î± MAP Kinase Inhibitors. Journal of Medicinal Chemistry, 2020, 63, 7347-7354.	6.4	14
12	Case Study on Receptor Tyrosine Kinases EGFR, VEGFR, and PDGFR. Topics in Medicinal Chemistry, 2020, , 155-201.	0.8	0
13	Novel phosphatidylinositol 4-kinases III beta (PI4KIIIÎ²) inhibitors discovered by virtual screening using free energy models. Journal of Computer-Aided Molecular Design, 2020, 34, 1091-1103.	2.9	4
14	Carbamoyl-N-aryl-imine-urea: a new framework to obtain a putative leishmanicidal drug-candidate. RSC Advances, 2020, 10, 12384-12394.	3.6	2
15	What is hidden in the biodiversity? The role of natural products and medicinal chemistry in the drug discovery process. Anais Da Academia Brasileira De Ciencias, 2019, 91, e20190306.	0.8	5
16	Reduction of cardiac and renal dysfunction by new inhibitor of DPP4 in diabetic rats. Pharmacological Reports, 2019, 71, 1190-1200.	3.3	5
17	LASSBio-596 protects gastric mucosa against the development of ethanol-induced gastric lesions in mice. European Journal of Pharmacology, 2019, 863, 172662.	3.5	7
18	Gastroprotective effects of N-acylarylhydrazone derivatives on ethanol-induced gastric lesions in mice are dependent on the NO/cGMP/KATP pathway. Biochemical Pharmacology, 2019, 169, 113629.	4.4	14

#	Article	IF	Citations
19	Evaluation of Functional Selectivity of Haloperidol, Clozapine, and LASSBio-579, an Experimental Compound With Antipsychotic-Like Actions in Rodents, at G Protein and Arrestin Signaling Downstream of the Dopamine D2 Receptor. Frontiers in Pharmacology, 2019, 10, 628.	3.5	2
20	Semicarbazone derivatives as promising therapeutic alternatives in leishmaniasis. Experimental Parasitology, 2019, 201, 57-66.	1.2	8
21	A novel scaffold for EGFR inhibition: Introducing N-(3-(3-phenylureido)quinoxalin-6-yl) acrylamide derivatives. Scientific Reports, 2019, 9, 14.	3.3	28
22	Chemical Intuition in Drug Design and Discovery. Current Topics in Medicinal Chemistry, 2019, 19, 1679-1693.	2.1	10
23	Oxidative imbalance in mice intoxicated by microcystin-LR can be minimized. Toxicon, 2018, 144, 75-82.	1.6	4
24	Ru(II) Compounds: Next-Generation Anticancer Metallotherapeutics?. Journal of Medicinal Chemistry, 2018, 61, 5805-5821.	6.4	343
25	Lung and liver responses to 1- and 7-day treatments with LASSBio-596 in mice subchronically intoxicated by microcystin-LR. Toxicon, 2018, 141, 1-8.	1.6	6
26	Discovery of naphthylâ€Nâ€acylhydrazone p38Î± MAPK inhibitors with in vivo antiâ€inflammatory and antiâ€TNFâ€Î± activity. Chemical Biology and Drug Design, 2018, 91, 391-397.	3.2	22
27	Synthesis, Pharmacological Evaluation and Docking Study of a New Modulator of Microtubule Polymerization. Letters in Drug Design and Discovery, 2018, 15, 778-786.	0.7	4
28	Design, Synthesis, Experimental and Theoretical Characterization of a New Multitarget 2-Thienyl-N-Acylhydrazone Derivative. Pharmaceuticals, 2018, 11, 119.	3.8	7
29	Potent immunosuppressive activity of a phosphodiesterase-4 inhibitor N-acylhydrazone in models of lipopolysaccharide-induced shock and delayed-type hypersensitivity reaction. International Immunopharmacology, 2018, 65, 108-118.	3.8	6
30	LASSBio-1586, an N-acylhydrazone derivative, attenuates nociceptive behavior and the inflammatory response in mice. PLoS ONE, 2018, 13, e0199009.	2.5	5
31	Synthesis, X-ray diffraction study and pharmacological evaluation of 3-amino-4-methylthiophene-2-acylcarbohydrazones. Anais Da Academia Brasileira De Ciencias, 2018, 90, 1073-1088.	0.8	3
32	N-Acylhydrazones as drugs. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 2797-2806.	2.2	140
33	The novel piperazine-containing compound LQFM018: Necroptosis cell death mechanisms, dopamine D4 receptor binding and toxicological assessment. Biomedicine and Pharmacotherapy, 2018, 102, 481-493.	5.6	12
34	Synergistic interaction between a PDE5 inhibitor (sildenafil) and a new adenosine A2A receptor agonist (LASSBio-1359) improves pulmonary hypertension in rats. PLoS ONE, 2018, 13, e0195047.	2.5	8
35	Structural Characteristics of Protein Kinases and Their Inhibitors in Clinical Use. Revista Virtual De Quimica, 2018, 10, 1280-1303.	0.4	2
36	Recent Advances in Development of Polyphenols as Anticancer Agents. Mini-Reviews in Medicinal Chemistry, 2018, 18, 1265-1269.	2.4	13

#	Article	IF	Citations
37	Synthesis, Aqueous Solubility, Metabolic Stability and Pharmacological Profile of Simplified Urea Derivatives. Letters in Drug Design and Discovery, 2018, 15, 766-777.	0.7	3
38	The Bench of Science. Revista Virtual De Quimica, 2018, 10, 1-1.	0.4	2
39	A combined experimental and in silico characterization to highlight additional structural features and properties of a potentially new drug. Journal of Molecular Structure, 2017, 1146, 735-743.	3.6	3
40	Structural and physicochemical characterization of sulfonylhydrazone derivatives designed as hypoglycemic agents. New Journal of Chemistry, 2017, 41, 6464-6474.	2.8	6
41	The antithrombotic and haemostatic effects of LASSBio-752: a synthetic, orally active compound in an arterial and venous thrombosis model in rats. Journal of Pharmacy and Pharmacology, 2017, 69, 1374-1380.	2.4	3
42	Structural characterization and cytotoxicity studies of different forms of a combretastatin A4 analogue. Journal of Molecular Structure, 2017, 1147, 226-234.	3.6	10
43	Adenosine Receptors As Drug Targets for Treatment of Pulmonary Arterial Hypertension. Frontiers in Pharmacology, 2017, 8, 858.	3.5	27
44	Adenosine A_{2A} receptor agonist prevents cardiac remodeling and dysfunction in spontaneously hypertensive male rats after myocardial infarction. Drug Design, Development and Therapy, 2017, Volume11, 553-562.	4.3	31
45	Resposta Ã CiÃªncia AmeaÃ§ada. Revista Virtual De Quimica, 2017, 9, 1393-1393.	0.4	0
46	Synthesis, solubility, plasma stability, and pharmacological evaluation of novel sulfonylhydrazones designed as anti-diabetic agents. Drug Design, Development and Therapy, 2016, Volume 10, 2869-2879.	4.3	12
47	Treatment with Adenosine Receptor Agonist Ameliorates Pain Induced by Acute and Chronic Inflammation. Journal of Pharmacology and Experimental Therapeutics, 2016, 358, 315-323.	2.5	18
48	Design, synthesis, structural characterization and in vitro cytotoxic activity of mononuclear Ru(II)complexes. Medicinal Chemistry Research, 2016, 25, 2127-2132.	2.4	1
49	LASSBio-579, a prototype antipsychotic drug, and clozapine are effective in novel object recognition task, a recognition memory model. Behavioural Pharmacology, 2016, 27, 339-349.	1.7	7
50	The total synthesis of calcium atorvastatin. Organic and Biomolecular Chemistry, 2016, 14, 2291-2296.	2.8	22
51	Respiratory and Systemic Effects of LASSBio596 Plus Surfactant in Experimental Acute Respiratory Distress Syndrome. Cellular Physiology and Biochemistry, 2016, 38, 821-835.	1.6	10
52	LASSBio-1425, an analog of thalidomide, decreases triglyceride and increases HDL cholesterol levels by inhibition of TNF-Î± production. International Journal of Cardiology, 2016, 202, 497-499.	1.7	9
53	Synthesis, characterization, DNA binding, DNA cleavage, protein binding and cytotoxic activities of Ru(II) complexes. International Journal of Biological Macromolecules, 2016, 82, 663-670.	7.5	33
54	Synthesis, Pharmacological Profile and Docking Studies of New Sulfonamides Designed as Phosphodiesterase-4 Inhibitors. PLoS ONE, 2016, 11, e0162895.	2.5	10

#	Article	IF	Citations
55	Novel Orally Active Analgesic and Anti-Inflammatory Cyclohexyl-N-Acylhydrazone Derivatives. Molecules, 2015, 20, 3067-3088.	3.8	39
56	Therapeutic effects of LASSBio-596 in an elastase-induced mouse model of emphysema. Frontiers in Physiology, 2015, 6, 267.	2.8	18
57	Structural feature evolution â€“ from fluids to the solid phase â€“ and crystal morphology study of LASSBio 1601: a cyclohexyl-N-acylhydrazone derivative. RSC Advances, 2015, 5, 39889-39898.	3.6	6
58	Structural characterization of LASSBio-1289: a new vasoactive N-methyl-N-acylhydrazone derivative. CrystEngComm, 2015, 17, 165-173.	2.6	10
59	Design, synthesis and inÂvitro trypanocidal and leishmanicidal activities of novel semicarbazone derivatives. European Journal of Medicinal Chemistry, 2015, 100, 24-33.	5.5	18
60	Novel Agonist of Adenosine Receptor Induces Relaxation of Corpus Cavernosum in Guinea Pigs: An InÂVitro and InÂVivo Study. Urology, 2015, 85, 1214.e17-1214.e21.	1.0	4
61	Investigating the therapeutic effects of LASSBio-596 in an inÂvivo model of cylindrospermopsin-induced lung injury. Toxicon, 2015, 94, 29-35.	1.6	11
62	Partial agonism and fast dissociation of LASSBio-579 at dopamine D2 receptor. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2015, 62, 1-6.	4.8	4
63	Design, synthesis, characterization, cytotoxic and structure activity relationships of novel Ru(II) complexes. Chinese Chemical Letters, 2015, 26, 721-726.	9.0	12
64	In vivo effect of LASSBio-785, a lipid-lowering and anti-inflammatory agent, on cardiac Ca2+-ATPases from hypercholesterolemic rats. International Journal of Cardiology, 2015, 201, 282-284.	1.7	2
65	Synthesis and Biological Evaluation of Pyrazolo[3,4-<i>b</i>]pyridin-4-ones as a New Class of Topoisomerase II Inhibitors. Medicinal Chemistry, 2015, 11, 342-353.	1.5	6
66	3-Aminothiophene-2-Acylhydrazones: Non-Toxic, Analgesic and Anti-Inflammatory Lead-Candidates. Molecules, 2014, 19, 8456-8471.	3.8	10
67	Novel Potent Imidazo[1,2-a]pyridine-N-Glycinyl-Hydrazone Inhibitors of TNF-Î± Production: In Vitro and In Vivo Studies. PLoS ONE, 2014, 9, e91660.	2.5	16
68	Vasodilator and antihypertensive effects of a novel <scp>N</scp>â€acylhydrazone derivative mediated by the inhibition of <scp>L</scp>â€type Ca²⁺ channels. Fundamental and Clinical Pharmacology, 2014, 28, 29-41.	1.9	8
69	Novel 2-chloro-4-anilino-quinazoline derivatives as EGFR and VEGFR-2 dual inhibitors. European Journal of Medicinal Chemistry, 2014, 71, 1-14.	5.5	109
70	N-acylhydrazone derivative ameliorates monocrotaline-induced pulmonary hypertension through the modulation of adenosine AA2R activity. International Journal of Cardiology, 2014, 173, 154-162.	1.7	36
71	N-acylhydrazone improves exercise intolerance in rats submitted to myocardial infarction by the recovery of calcium homeostasis in skeletal muscle. Life Sciences, 2014, 94, 30-36.	4.3	10
72	Docking, Synthesis and Antiproliferative Activity of N-Acylhydrazone Derivatives Designed as Combretastatin A4 Analogues. PLoS ONE, 2014, 9, e85380.	2.5	50

#	Article	IF	Citations
73	LASSBio-1135: A Dual TRPV1 Antagonist and Anti-TNF-Alpha Compound Orally Effective in Models of Inflammatory and Neuropathic Pain. PLoS ONE, 2014, 9, e99510.	2.5	13
74	In Vitro Microsomal Hepatic Metabolism of Antiasthmatic Prototype LASSBio-448. Current Topics in Medicinal Chemistry, 2014, 14, 1388-1398.	2.1	4
75	Biotransformation of LASSBio-579 and pharmacological evaluation of p -hydroxylated metabolite a N -phenylpiperazine antipsychotic lead compound. European Journal of Medicinal Chemistry, 2013, 62, 214-221.	5.5	14
76	A novel CaÂ²+ channel antagonist reverses cardiac hypertrophy and pulmonary arteriolar remodeling in experimental pulmonary hypertension. European Journal of Pharmacology, 2013, 702, 316-322.	3.5	14
77	Hybrid furoxanyl N-acylhydrazone derivatives as hits for the development of neglected diseases drug candidates. European Journal of Medicinal Chemistry, 2013, 59, 64-74.	5.5	57
78	New oxidovanadium(IV) N -acylhydrazone complexes: Promising antileishmanial and antitrypanosomal agents. European Journal of Medicinal Chemistry, 2013, 62, 20-27.	5.5	57
79	Synthesis and pharmacological evaluation of new N-phenylpiperazine derivatives designed as homologues of the antipsychotic lead compound LASSBio-579. European Journal of Medicinal Chemistry, 2013, 66, 122-134.	5.5	25
80	Beneficial effects of a novel agonist of the adenosine <scp>A_{2A}</scp> receptor on monocrotalineâ€induced pulmonary hypertension in rats. British Journal of Pharmacology, 2013, 169, 953-962.	5.4	37
81	New insights into pharmacological profile of LASSBio-579, a multi-target N-phenylpiperazine derivative active on animal models of schizophrenia. Behavioural Brain Research, 2013, 237, 86-95.	2.2	26
82	Antihyperalgesic effects of a novel muscarinic agonist (<scp>LASSB</scp>ioâ€873) in spinal nerve ligation in rats. Clinical and Experimental Pharmacology and Physiology, 2013, 40, 404-411.	1.9	8
83	Anti-atherogenic Effects of a New Thienylacylhydrazone Derivative, LASSBio-788, in Rats Fed a Hypercholesterolemic Diet. Journal of Pharmacological Sciences, 2013, 123, 47-57.	2.5	15
84	Structure Re-determination of LASSBio-294 â€“ a cardioactive compound of the N-acylhydrazone class â€“ using X-ray powder diffraction data. Powder Diffraction, 2013, 28, S491-S509.	0.2	12
85	Characterization of Amide Bond Conformers for a Novel Heterocyclic Template of N-acylhydrazone Derivatives. Molecules, 2013, 18, 11683-11704.	3.8	82
86	Oral Antithrombotic Effects of Acylhydrazone Derivatives. Journal of Atherosclerosis and Thrombosis, 2013, 20, 287-295.	2.0	7
87	Desafios da indÃºstria farmacÃªutica brasileira. Quimica Nova, 2013, 36, 1557-1560.	0.3	3
88	Opportunities and Challenges for Innovation in Pharmaceuticals: Now or Never!. Revista Virtual De Quimica, 2013, 5, .	0.4	1
89	Pharmaceutical sciences scenario in CNPq research fellowship. Brazilian Journal of Pharmaceutical Sciences, 2013, 49, V-VI.	1.2	0
90	LASSBio-542: Novel Thalidomide Analog Distinctly Modulates IL-10 and Inhibits Angiogenesis. Current Bioactive Compounds, 2012, 8, 167-175.	0.5	0

#	Article	IF	Citations
91	Docking, Synthesis and Anti-Diabetic Activity of Novel Sulfonylhydrazone Derivatives Designed as PPAR-Gamma Agonists. Current Topics in Medicinal Chemistry, 2012, 12, 2037-2048.	2.1	14
92	Design, Synthesis, Antinociceptive and Anti-Inflammatory Activities of Novel Piroxicam Analogues. Molecules, 2012, 17, 14126-14145.	3.8	20
93	Docking, synthesis and pharmacological activity of novel urea-derivatives designed as p38 MAPK inhibitors. European Journal of Medicinal Chemistry, 2012, 54, 264-271.	5.5	14
94	Potential Inhibitory Effect of LASSBio-596, a New Thalidomide Hybrid, on Inflammatory Corneal Angiogenesis in Rabbits. Ophthalmic Research, 2012, 48, 177-185.	1.9	12
95	Novel furfurylidene N-acylhydrazones derived from natural safrole: discovery of LASSBio-1215, a new potent antiplatelet prototype. Journal of Enzyme Inhibition and Medicinal Chemistry, 2012, 27, 101-109.	5.2	6
96	Vasodilatory activity and antihypertensive profile mediated by inhibition of phosphodiesterase type 1 induced by a novel sulfonamide compound. Fundamental and Clinical Pharmacology, 2012, 26, 690-700.	1.9	11
97	Benzenesulfonamide attenuates monocrotaline-induced pulmonary arterial hypertension in a rat model. European Journal of Pharmacology, 2012, 690, 176-182.	3.5	9
98	Design, Synthesis, and Pharmacological Evaluation of N-Acylhydrazones and Novel Conformationally Constrained Compounds as Selective and Potent Orally Active Phosphodiesterase-4 Inhibitors. Journal of Medicinal Chemistry, 2012, 55, 7525-7545.	6.4	105
99	Antihypertensive profile of 2-thienyl-3,4-methylenedioxybenzoylhydrazone isÂmediated by activation of the A2A adenosine receptor. European Journal of Medicinal Chemistry, 2012, 55, 49-57.	5.5	36
100	Synthesis and Pharmacological Evaluation of Novel Phenyl Sulfonamide Derivatives Designed as Modulators of Pulmonary Inflammatory Response. Molecules, 2012, 17, 14651-14672.	3.8	9
101	Discovery of Novel Orally Active Anti-Inflammatory N-Phenylpyrazolyl-N-Glycinyl-Hydrazone Derivatives That Inhibit TNF-Î± Production. PLoS ONE, 2012, 7, e46925.	2.5	21
102	Molecular docking and molecular dynamic studies of semi-synthetic piperidine alkaloids as acetylcholinesterase inhibitors. Journal of the Brazilian Chemical Society, 2012, 23, 163-170.	0.6	6
103	Antinociceptive effects of an extract, fraction and an isolated compound of the stem bark of Maytenus rigida. Revista Brasileira De Farmacognosia, 2012, 22, 598-603.	1.4	9
104	Synthesis and characterization of the atropisomeric relationships of a substituted Nâ€phenylâ€bipyrazole derivative with antiâ€inflammatory properties. Chirality, 2012, 24, 463-470.	2.6	2
105	Combination of docking, molecular dynamics and quantum mechanical calculations for metabolism prediction of 3,4-methylenedioxybenzoyl-2-thienylhydrazone. Journal of Molecular Modeling, 2012, 18, 2065-2078.	1.8	23
106	Discovery of new orally effective analgesic and anti-inflammatory hybrid furoxanyl N-acylhydrazone derivatives. Bioorganic and Medicinal Chemistry, 2012, 20, 2158-2171.	3.0	62
107	Synthesis, Biological Evaluation, and Structureâ€“activity Relationship of Clonazepam, Meclonazepam, and 1,4â€Benzodiazepine Compounds with Schistosomicidal Activity. Chemical Biology and Drug Design, 2012, 79, 943-949.	3.2	26
108	Anti-inflammatory effects of LASSBio-998, a new drug candidate designed to be a p38 MAPK inhibitor, in an experimental model of acute lung inflammation. Pharmacological Reports, 2011, 63, 1029-1039.	3.3	14

#	Article	IF	Citations
109	LASSBio 596 per os avoids pulmonary and hepatic inflammation induced by microcystin-LR. Toxicon, 2011, 58, 195-201.	1.6	20
110	Therapeutic approaches for tumor necrosis factor inhibition. Brazilian Journal of Pharmaceutical Sciences, 2011, 47, 427-446.	1.2	13
111	New Pyrazolylhydrazone Derivatives as Inhibitors of Platelet Aggregation. Journal of Pharmacy and Pharmacology, 2011, 45, 646-649.	2.4	20
112	Analgesic and Anti-Inflammatory Activities of Salicylaldehyde 2-Chlorobenzoyl Hydrazone (H2LASSBio-466), Salicylaldehyde 4-Chlorobenzoyl Hydrazone (H2LASSBio-1064) and Their Zinc(II) Complexes. Molecules, 2011, 16, 6902-6915.	3.8	48
113	The Methylation Effect in Medicinal Chemistry. Chemical Reviews, 2011, 111, 5215-5246.	47.7	671
114	Discovery of LASSBio-772, a 1,3-benzodioxole N-phenylpiperazine derivative with potent alpha 1A/D-Adrenergic receptor blocking properties. European Journal of Medicinal Chemistry, 2011, 46, 3000-3012.	5.5	32
115	CYP1A2-mediated biotransformation of cardioactive 2-thienylidene-3,4-methylenedioxybenzoylhydrazine (LASSBio-294) by rat liver microsomes and human recombinant CYP enzymes. European Journal of Medicinal Chemistry, 2011, 46, 349-355.	5.5	7
116	Structure-based design and biological profile of (E)-N-(4-Nitrobenzylidene)-2-naphthohydrazide, a novel small molecule inhibitor of Ì¦B kinase-Î². European Journal of Medicinal Chemistry, 2011, 46, 1245-1253.	5.5	22
117	Determination of the cardioactive prototype LASSBio-294 and its metabolites in dog plasma by LCâ€“MS/MS: Application for a pharmacokinetic study. Journal of Pharmaceutical and Biomedical Analysis, 2011, 55, 1024-1030.	2.8	7
118	Binuclear zinc(II) complexes with the anti-inflammatory compounds salicylaldehyde semicarbazone and salicylaldehyde-4-chlorobenzoyl hydrazone (H2LASSBio-1064). Polyhedron, 2011, 30, 1891-1898.	2.2	39
119	MAOS and Medicinal Chemistry: Some Important Examples from the Last Years. Molecules, 2011, 16, 9274-9297.	3.8	18
120	The Role of Natural Products in the Discovery of New Drug Candidates for the Treatment of Neurodegenerative Disorders II: Alzheimers Disease. CNS and Neurological Disorders - Drug Targets, 2011, 10, 251-270.	1.4	93
121	The Role of Natural Products in the Discovery of New Drug Candidates for the Treatment of Neurodegenerative Disorders I: Parkinsons Disease. CNS and Neurological Disorders - Drug Targets, 2011, 10, 239-250.	1.4	32
122	Cardiovascular Effects of a Novel Synthetic Analogue of Naturally Occurring Piperamides. Journal of Cardiovascular Pharmacology, 2010, 56, 293-299.	1.9	1
123	Respiratory And Systemic Effects Of LASSBio596 Associated Or Not With Surfactant In An Experimental Model Of Sepsis-induced Acute Lung Injury. , 2010, , .		0
124	Anti-inflammatory Profile of N-Phenylpyrazole Arylhydrazone Derivatives in Rats. Journal of Pharmacy and Pharmacology, 2010, 51, 703-707.	2.4	8
125	Pharmacokinetic evaluation of LASSBio-579: an N-phenylpiperazine antipsychotic prototype. Journal of Pharmacy and Pharmacology, 2010, 60, 699-707.	2.4	33
126	2-Acetylpyridine thiosemicarbazones: Cytotoxic activity in nanomolar doses against malignant gliomas. European Journal of Medicinal Chemistry, 2010, 45, 5671-5677.	5.5	63

#	Article	IF	Citations
127	Searching for multi-target antipsychotics: Discovery of orally active heterocyclic N-phenylpiperazine ligands of D2-like and 5-HT1A receptors. Bioorganic and Medicinal Chemistry, 2010, 18, 1925-1935.	3.0	57
128	Synthesis and pharmacological evaluation of pyrazine N-acylhydrazone derivatives designed as novel analgesic and anti-inflammatory drug candidates. Bioorganic and Medicinal Chemistry, 2010, 18, 5007-5015.	3.0	53
129	Novel thienylacylhydrazone derivatives inhibit platelet aggregation through cyclic nucleotides modulation and thromboxane A2 synthesis inhibition. European Journal of Pharmacology, 2010, 638, 5-12.	3.5	25
130	Characterization of the conformational ensemble from bioactive N-acylhydrazone derivatives. Journal of Molecular Graphics and Modelling, 2010, 28, 446-454.	2.4	12
131	Design of new dopamine D2 receptor ligands: Biosynthesis and pharmacological evaluation of the hydroxylated metabolite of LASSBio-581. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 2888-2891.	2.2	7
132	Microwave-assisted synthesis and structureâ€“activity relationships of neuroactive pyrazolo[3,4-b]pyrrolo[3,4-d]pyridine derivatives. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 74-77.	2.2	39
133	Structure-based prediction and biosynthesis of the major mammalian metabolite of the cardioactive prototype LASSBio-294. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 3734-3736.	2.2	14
134	Antimicrobial activity of Pterogyne nitens Tul., Fabaceae, against opportunistic fungi. Revista Brasileira De Farmacognosia, 2010, 20, 706-711.	1.4	19
135	Pharmacological Characterization of (3-Thienylidene)-3,4-Methylenedioxybenzoylhydrazide: A Novel Muscarinic Agonist With Antihypertensive Profile. American Journal of Hypertension, 2010, 23, 135-141.	2.0	19
136	Can LASSBio 596 and dexamethasone treat acute lung and liver inflammation induced by microcystin-LR?. Toxicon, 2010, 56, 604-612.	1.6	25
137	Cardiovascular effects induced by N-(4'-dihydro)-piperoylthiomorpholine in normotensive rats. Journal of Pharmacy and Pharmacology, 2010, 62, 1794-1800.	2.4	0
138	LASSBio-596: Of the discovery to the pre-clinical studies. Revista Virtual De Quimica, 2010, 2, .	0.4	1
139	Spectaline, cassine and semi-synthetic analogues as potential candidate drugs for the treatment of Alzheimer disease. Revista Virtual De Quimica, 2010, 2, .	0.4	2
140	Editorial - fÃ¡rmacos genÃ©ricos: importÃ¡-los atÃ© quando?. Journal of the Brazilian Chemical Society, 2010, 21, 775-775.	0.6	1
141	Discovery of novel heteroarylazoleN-phenylpiperazine prototypes candidates to atypic antipsychotic drugs. Revista Virtual De Quimica, 2010, 2, .	0.4	0
142	ESPECIAL DEDICADO AO INCT-INOFAR. Revista Virtual De Quimica, 2010, 2, .	0.4	0
143	A Theoretical Investigation on the Pleiotropic Effects of Statins as p38 MAP Kinase Ligands. Letters in Drug Design and Discovery, 2010, 7, 546-550.	0.7	0
144	Biodiversidade: fonte potencial para a descoberta de fÃ¡rmacos. Quimica Nova, 2009, 32, 679-688.	0.3	51

#	Article	IF	Citations
145	Sedation and antinociception induced by a new pyrazolo[3,4-b]pyrrolo[3,4-d]pyridine derivative (LASSBio-873) is modulated by activation of muscarinic receptors. Pharmacology Biochemistry and Behavior, 2009, 94, 70-74.	2.9	19
146	Synthesis and pharmacological evaluation of N-phenyl-acetamide sulfonamides designed as novel non-hepatotoxic analgesic candidates. European Journal of Medicinal Chemistry, 2009, 44, 3612-3620.	5.5	17
147	Studies towards the identification of putative bioactive conformation of potent vasodilator arylidene N-acylhydrazone derivatives. European Journal of Medicinal Chemistry, 2009, 44, 4004-4009.	5.5	71
148	Synthesis, pharmacological evaluation and docking studies of new sulindac analogues. European Journal of Medicinal Chemistry, 2009, 44, 1959-1971.	5.5	10
149	Discovery of novel analgesic and anti-inflammatory 3-arylamine-imidazo[1,2-a]pyridine symbiotic prototypes. Bioorganic and Medicinal Chemistry, 2009, 17, 74-84.	3.0	187
150	Synthesis, trypanocidal activity and docking studies of novel quinoxaline-N-acylhydrazones, designed as cruzain inhibitors candidates. Bioorganic and Medicinal Chemistry, 2009, 17, 641-652.	3.0	94
151	Novel 6-methanesulfonamide-3,4-methylenedioxyphenyl-N-acylhydrazones: Orally effective anti-inflammatory drug candidates. Bioorganic and Medicinal Chemistry, 2009, 17, 1125-1131.	3.0	35
152	Synthesis and analgesic profile of conformationally constrained N-acylhydrazone analogues: Discovery of novel N-arylideneamino quinazolin-4(3H)-one compounds derived from natural safrole. Bioorganic and Medicinal Chemistry, 2009, 17, 6517-6525.	3.0	24
153	Design, synthesis and analgesic properties of novel conformationally-restricted N-acylhydrazones (NAH). Bioorganic and Medicinal Chemistry Letters, 2009, 19, 4963-4966.	2.2	48
154	Structural insights into IKKÎ² inhibition by natural products staurosporine and quercetin. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 6907-6910.	2.2	13
155	Cytotoxic Guanidine Alkaloids from Pterogyne nitens. Journal of Natural Products, 2009, 72, 473-476.	3.0	40
156	From Nature to Drug Discovery: The Indole Scaffold as a ‘Privileged Structure’. Mini-Reviews in Medicinal Chemistry, 2009, 9, 782-793.	2.4	498
157	Medicinal Chemistry and the paradigm of the lead compound. Revista Virtual De Quimica, 2009, 1, .	0.4	2
158	Flavonols from Pterogyne nitens and their evaluation as myeloperoxidase inhibitors. Phytochemistry, 2008, 69, 1739-1744.	2.9	67
159	Synthesis and anti-platelet activity of novel arylsulfonateâ€“acylhydrazone derivatives, designed as antithrombotic candidates. European Journal of Medicinal Chemistry, 2008, 43, 348-356.	5.5	60
160	NSAIDs revisited: Putative molecular basis of their interactions with peroxisome proliferator-activated gamma receptor (PPARÎ³). European Journal of Medicinal Chemistry, 2008, 43, 1918-1925.	5.5	7
161	CNS-selective noncompetitive cholinesterase inhibitors derived from the natural piperidine alkaloid (â^')-spectaline. European Journal of Pharmacology, 2008, 580, 339-349.	3.5	34
162	Serotonergic neurotransmission mediates hypothermia induced by the N-phenylpiperazine antipsychotic prototypes LASSBio-579 and LASSBio-581. Pharmacology Biochemistry and Behavior, 2008, 89, 23-30.	2.9	14

#	Article	IF	Citations
163	Improved Solventâ€Free Dakin Oxidation Protocol. Synthetic Communications, 2008, 38, 784-788.	2.1	27
164	Antinociceptive Profile of 2,3,6-Trisubstituted Piperidine Alkaloids: 3-O-Acetyl-spectaline and Semi-synthetic Derivatives of (-)-Spectaline. Chemical and Pharmaceutical Bulletin, 2008, 56, 407-412.	1.3	23
165	1-Methyl-7-(4-nitrophenyl)-3-phenylpyrazolo[3,4-b]pyrrolo[3,4-d]pyridine-6,8(3H,7H)-dione. Acta Crystallographica Section E: Structure Reports Online, 2008, 64, o2356-o2356.	0.2	0
166	Constituintes quÃmicos das flores de Pterogyne nitens (Caesalpinioideae). Quimica Nova, 2008, 31, 802-806.	0.3	24
167	Molecular Hybridization: A Useful Tool in the Design of New Drug Prototypes. Current Medicinal Chemistry, 2007, 14, 1829-1852.	2.4	930
168	Privileged Structures: A Useful Concept for the Rational Design of New Lead Drug Candidates. Mini-Reviews in Medicinal Chemistry, 2007, 7, 1108-1119.	2.4	266
169	The Molecular Basis of COX-2 Versus COX-1 Selectivity of Lumiracoxib by Molecular Docking Studies. Letters in Drug Design and Discovery, 2007, 4, 422-425.	0.7	3
170	High performance liquid chromatography method for quantification of the N-phenylpiperazine derivative LASSBio-579 in rat plasma. Quimica Nova, 2007, 30, 1919-1922.	0.3	1
171	Synthesis, pharmacological evaluation and electrochemical studies of novel 6-nitro-3,4-methylenedioxyphenyl-N-acylhydrazone derivatives: Discovery of LASSBio-881, a new ligand of cannabinoid receptors. Bioorganic and Medicinal Chemistry, 2007, 15, 2421-2433.	3.0	59
172	Thalidomide and Analogs as Anti-Inflammatory and Immunomodulator Drug Candidates. Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry, 2006, 5, 79-95.	1.1	5
173	Os produtos naturais e a quÃmica medicinal moderna. Quimica Nova, 2006, 29, 326-337.	0.3	93
174	New potent 5-nitrofuryl derivatives asÂinhibitors ofÂTrypanosomaÂcruzi growth. 3D-QSAR (CoMFA) studies. European Journal of Medicinal Chemistry, 2006, 41, 457-466.	5.5	23
175	Molecular docking study and development of an empirical binding free energy model for phosphodiesterase 4 inhibitors. Bioorganic and Medicinal Chemistry, 2006, 14, 6001-6011.	3.0	15
176	Development of new CoMFA and CoMSIA 3D-QSAR models for anti-inflammatory phthalimide-containing TNFÎ± modulators. Bioorganic and Medicinal Chemistry, 2006, 14, 6874-6885.	3.0	16
177	Design and synthesis of 3,4-methylenedioxy-6-nitrophenoxyacetylhydrazone derivatives obtained from natural safrole: New lead-agents with analgesic and antipyretic properties. Bioorganic and Medicinal Chemistry, 2006, 14, 7924-7935.	3.0	80
178	Design, synthesis, and pharmacological evaluation of new neuroactive pyrazolo[3,4-b]pyrrolo[3,4-d]pyridine derivatives with in vivo hypnotic and analgesic profile. Bioorganic and Medicinal Chemistry, 2006, 14, 632-640.	3.0	41
179	Medicinal Chemistry of N-Acylhydrazones: New Lead-Compounds of Analgesic, Antiinflammatory and Antithrombotic Drugs. Current Medicinal Chemistry, 2006, 13, 167-198.	2.4	95
180	Chemo-selective hydrolysis of the iminic moiety in salicylaldehyde semicarbazone promoted by ruthenium. Inorganica Chimica Acta, 2005, 358, 3065-3074.	2.4	17

#	Article	IF	Citations
181	Synthesis and vasodilatory activity of new N-acylhydrazone derivatives, designed as LASSBio-294 analogues. Bioorganic and Medicinal Chemistry, 2005, 13, 3431-3437.	3.0	87
182	New selective acetylcholinesterase inhibitors designed from natural piperidine alkaloids. Bioorganic and Medicinal Chemistry, 2005, 13, 4184-4190.	3.0	48
183	A proposed molecular basis for the selective resveratrol inhibition of the PGHS-1 peroxidase activity. Bioorganic and Medicinal Chemistry, 2005, 13, 5981-5985.	3.0	2
184	New potent 5-substituted benzofuroxans as inhibitors of Trypanosoma cruzi growth: Quantitative structureâ€“activity relationship studies. Bioorganic and Medicinal Chemistry, 2005, 13, 6336-6346.	3.0	36
185	Design, synthesis and antiinflammatory activity of novel phthalimide derivatives, structurally related to thalidomide. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 1169-1172.	2.2	70
186	Hydrolysis of New Phthalimide-Derived Esters Catalyzed by Immobilized Lipase. Applied Biochemistry and Biotechnology, 2005, 121, 0117-0128.	2.9	5
187	Evaluating the prophylactic potential of the phtalimide derivative LASSBio 552 on allergen-evoked inflammation in rats. European Journal of Pharmacology, 2005, 511, 219-227.	3.5	2
188	Electrospray ionization mass and tandem mass spectra of a series ofN-pyrazolylmethyl andN-triazolylmethylN-phenylpiperazines: new dopaminergic ligands with potential antipsychotic properties. Journal of Mass Spectrometry, 2005, 40, 815-820.	1.6	13
189	The molecular basis for coxib inhibition of p38Î± MAP kinase. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 3506-3509.	2.2	13
190	Um paradigma da quÃmica medicinal: a flexibilidade dos ligantes e receptores. Quimica Nova, 2005, 28, 95-102.	0.3	5
191	New Anti-Alzheimer Drugs from Biodiversity: The Role of the Natural Acetylcholinesterase Inhibitors. Mini-Reviews in Medicinal Chemistry, 2005, 5, 915-926.	2.4	39
192	Bioisosterism: A Useful Strategy for Molecular Modification and Drug Design. Current Medicinal Chemistry, 2005, 12, 23-49.	2.4	563
193	LASSBio-468: a new achiral thalidomide analogue which modulates TNF-Î± and NO production and inhibits endotoxic shock and arthritis in an animal model. International Immunopharmacology, 2005, 5, 485-494.	3.8	19
194	AplicaÃ§Ã£o de anÃ¡lise de componentes principais para verificaÃ§Ã£o de atribuiÃ§Ãµes de sinais nos espetros de RMN Â¹H: o caso dos 3-aril (1,2,4)-oxadiazol-5-carboidrazida benzilidenos. Quimica Nova, 2005, 28, 492-496.	0.3	5
195	Hydrolysis of New Phthalimide-Derived Esters Catalyzed by Immobilized Lipase. , 2005, , 117-128.		0
196	Esquizofrenia: quarenta anos da hipÃ³tese dopaminÃ©rgica sob a Ã³tica da QuÃmica Medicinal. Quimica Nova, 2004, 27, 447-455.	0.3	5
197	New optimized piperamide analogues with potent in vivo hypotensive properties. European Journal of Pharmaceutical Sciences, 2004, 23, 363-369.	4.0	26
198	Further Bioactive Piperidine Alkaloids from the Flowers and Green Fruits ofCassiaspectabilis. Journal of Natural Products, 2004, 67, 908-910.	3.0	104

#	Article	IF	Citations
199	Studies on diastereoselective reduction of cyclic Î²-ketoesters with boron hydrides. Part 4: The reductive profile of functionalized cyclohexanone derivatives. Tetrahedron, 2004, 60, 2745-2755.	1.9	28
200	A novel 3D-QSAR comparative molecular field analysis (CoMFA) model of imidazole and quinazolinone functionalized p38 MAP kinase inhibitors. Bioorganic and Medicinal Chemistry, 2004, 12, 3159-3166.	3.0	50
201	New class of potent antinociceptive and antiplatelet 10H-phenothiazine-1-acylhydrazone derivatives. Bioorganic and Medicinal Chemistry, 2004, 12, 3149-3158.	3.0	125
202	Enzymatic hydrolysis by immobilized lipase applied to a new prototype anti-asthma drug. Biochemical Engineering Journal, 2004, 21, 103-110.	3.6	9
203	Produtos naturais como candidatos a fÃ¡rmacos Ãºteis no tratamento do Mal de Alzheimer. Quimica Nova, 2004, 27, 655-660.	0.3	26
204	Thienylhydrazone derivative increases sarcoplasmic reticulum Ca2+ release in mammalian skeletal muscle. European Journal of Pharmacology, 2003, 470, 79-85.	3.5	10
205	Synthesis and Biological Evaluation of New Imidazo[1,2-a]pyridine Derivatives Designed as Mefloquine Analogues.. ChemInform, 2003, 34, no.	0.0	0
206	Synthesis and Pharmacological Evaluation of Novel Antinociceptive N-Substituted-phenylimidazolyl-4-acylhydrazone Derivatives.. ChemInform, 2003, 34, no.	0.0	0
207	Antiplatelet properties of novel N-substituted-phenyl-1,2,3-triazole-4-acylhydrazone derivatives. Bioorganic and Medicinal Chemistry, 2003, 11, 2051-2059.	3.0	168
208	Design, synthesis and pharmacological profile of novel dopamine D2 receptor ligands. Bioorganic and Medicinal Chemistry, 2003, 11, 4807-4813.	3.0	67
209	Chiral separation of Î³-butyrolactone derivatives by gas chromatography on 2,3-di-O-methyl-6-O-tert.-butyldimethylsilyl-Î²-cyclodextrin. Journal of Chromatography A, 2003, 985, 321-331.	3.7	11
210	Design, Synthesis, and Pharmacological Profile of Novel Fused Pyrazolo[4,3-d]pyridine and Pyrazolo[3,4-b][1,8]naphthyridine Isosteres:Â A New Class of Potent and Selective Acetylcholinesterase Inhibitors. Journal of Medicinal Chemistry, 2003, 46, 1144-1152.	6.4	101
211	Antinociceptive Profile of (-)-Spectaline: A Piperidine Alkaloid fromCassia leptophylla. Planta Medica, 2003, 69, 795-799.	1.3	23
212	Novas estratÃ©gias terapÃªuticas para o tratamento da depressÃ£o: uma visÃ£o da quÃmica medicinal. Quimica Nova, 2003, 26, 347-358.	0.3	10
213	STUDIES ON THE DIASTEREO- SELECTIVE REDUCTION OF 2-ACETYL-2-ALKYL- Î³-BUTYROLACTONES WITH BORON HYDRIDES*. Synthetic Communications, 2002, 32, 505-526.	2.1	10
214	Structureâ^'Activity Relationships of the Antimalarial Agent Artemisinin. 6. The Development of Predictive In Vitro Potency Models Using CoMFA and HQSAR Methodologies. Journal of Medicinal Chemistry, 2002, 45, 292-303.	6.4	78
215	A quÃmica medicinal de N-acilidrazonas: novos compostos-protÃ³tipos de fÃ¡rmacos analgÃ©sicos, antiinflamatÃ³rios e anti-trombÃ³ticos. Quimica Nova, 2002, 25, 129-148.	0.3	42
216	Agentes antiasmÃ¡ticos modernos: antagonistas de receptores de leucotrienos cisteÃnicos. Quimica Nova, 2002, 25, 825-834.	0.3	1

#	Article	IF	Citations
217	EstratÃ©gia de simplificaÃ§Ã£o molecular no planejamento racional de fÃ¡rmacos: a descoberta de novo agente cardioativo. Quimica Nova, 2002, 25, 1172-1180.	0.3	33
218	Synthesis and pharmacological evaluation of novel antinociceptive N-substituted-phenylimidazolyl-4-acylhydrazone derivatives. Il Farmaco, 2002, 57, 999-1007.	0.9	22
219	Synthesis and biological evaluation of new imidazo[1,2-a]pyridine derivatives designed as mefloquine analogues. Il Farmaco, 2002, 57, 825-832.	0.9	23
220	Molecular modeling of novel 1H-pyrazolo[3,4-b]pyridine derivatives designed as isosters of the antimalarial mefloquine. Computational and Theoretical Chemistry, 2002, 579, 31-39.	1.5	28
221	Design, synthesis and pharmacological evaluation of novel pyrazolo[3,4-b]thieno[2,3-d]pyridine acid derivatives: a new class of anti-inflammatory and anti-platelet agents. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 9-12.	2.2	16
222	Novel phthalimide derivatives, designed as leukotriene D4 receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 1533-1535.	2.2	24
223	Synthesis and anti-inflammatory activity of phthalimide derivatives, designed as new thalidomide analogues. Bioorganic and Medicinal Chemistry, 2002, 10, 3067-3073.	3.0	174
224	New isoxazole derivatives designed as nicotinic acetylcholine receptor ligand candidates. European Journal of Medicinal Chemistry, 2002, 37, 163-170.	5.5	37
225	Local intersection volume: a new 3D descriptor applied to develop a 3D-QSAR pharmacophore model for benzodiazepine receptor ligands. European Journal of Medicinal Chemistry, 2002, 37, 219-229.	5.5	27
226	Highly diastereoselective mercury-mediated synthesis of functionalized 2-azabicyclo[3.3.0]octane derivatives. Tetrahedron Letters, 2002, 43, 1607-1611.	1.4	12
227	Synthesis and pharmacological evaluation of a new 2-azabicyclo[3.3.0]octane derivative. Journal of the Brazilian Chemical Society, 2001, 12, 408.	0.6	7
228	SYNTHESIS OF NATURAL AMIDE ALKALOID PIPERDARDINE AND A NEW BIOACTIVE ANALOGUEâ€. Synthetic Communications, 2001, 31, 117-123.	2.1	10
229	Synthesis of Functionalized Î³-Spirolactone and 2-Oxabicyclo[3.3.0]octane Derivatives from Nucleophilic Oxirane Ring Opening. Tetrahedron, 2000, 56, 5289-5295.	1.9	8
230	Design and Synthesis of Novel Potent Antinociceptive Agents: Methyl-imidazolyl N-Acylhydrazone Derivatives. Bioorganic and Medicinal Chemistry, 2000, 8, 2243-2248.	3.0	47
231	Synthesis and analgesic activity of novel N-acylarylhydrazones and isosters, derived from natural safrole##This paper represents contribution # 36 of the LASSBio, UFRJ (Br.) (LASSBio,) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 Chemistry, 2000, 35, 187-203.	5.5	195
232	Synthesis and pharmacological evaluation of novel heterotricyclic acylhydrazone derivatives, designed as PAF antagonists. European Journal of Pharmaceutical Sciences, 2000, 11, 285-290.	4.0	37
233	Electron impact mass spectrometry of some 3-[3-(4-aryl)-1,2,4-oxadiazole-5-yl] acyl arylaldehyde hydrazone derivatives. Spectroscopy, 2000, 14, 115-120.	0.8	4
234	O-Alkylation of Bioactive Phthalimide Derivatives Under Microwave Irradiation in Dry Media. Synthetic Communications, 2000, 30, 3291-3306.	2.1	11

#	Article	IF	Citations
235	Chiral Gas Chromatographic Separation of 2-Oxabicyclo[3.3.0]octane Derivatives and Their Synthetic Precursors. Analytical Chemistry, 2000, 72, 3056-3062.	6.5	5
236	Title is missing!. Quimica Nova, 2000, 23, 719-719.	0.3	0
237	New antithrombotic aryl-sulfonylthiosemicarbazide derivatives synthesized from natural safrole. Journal of the Brazilian Chemical Society, 1999, 10, 421-428.	0.6	9
238	SYNTHESIS OF NEW ISOSTERIC HETEROTRICYCLIC DERIVATIVES: PYRAZOLO[3,4-b]THIENO[3,2-e]PYRIDINE, PYRAZOLO[3,4-b]PYRROLO[3,2-e]PYRIDINE AND FURO[2,3-b]PYRAZOLO[4,3-e]PYRIDINE. Heterocyclic Communications, 1999, 5, .	1.2	0
239	Synthesis and antiplatelet evaluation of novel aryl-sulfonamide derivatives, from natural safrole. Pharmaceutica Acta Helvetiae, 1999, 73, 281-292.	1.2	16
240	Studies on antiplatelet agents from natural safrole. Pharmaceutica Acta Helvetiae, 1999, 74, 19-28.	1.2	5
241	Synthesis and analgesic profile of novel N-containing heterocycle derivatives: arylidene 3-phenyl-1,2,4-oxadiazole-5-carbohydrazide. Il Farmaco, 1999, 54, 747-757.	0.9	31
242	Proposal of a new PAF pharmacophoric map by the AM1 method. European Journal of Pharmaceutical Sciences, 1999, 8, 309-315.	4.0	1
243	Synthesis of Piperamides and New Analogues from Natural Safrole. Synthetic Communications, 1999, 29, 263-273.	2.1	10
244	A utilizaÃ§Ã£o do safrol, principal componente quÃmico do Ã³leo de sassafrÃ¡z, na sÃntese de substÂncias bioativas na cascata do Ã¡cido araquidÃ´nico: antiinflamatÃ³rios, analgÃ©sicos e anti-trombÃ³ticos. Quimica Nova, 1999, 22, 744-759.	0.3	37
245	Synthesis and pharmacological evaluation of a new class of bicyclic phospholipids, designed as platelet activating factor antagonists. Il Farmaco, 1998, 53, 327-336.	0.9	8
246	Toward a platelet-activating factor pseudoreceptor: Semiempirical modeling of cation-Ï€ and hydrogen bond interactions in agonist binding. Computational and Theoretical Chemistry, 1998, 429, 217-227.	1.5	4
247	Synthesis and pharmacological evaluation of new flosulide analogues, synthesized from natural safrole. Bioorganic and Medicinal Chemistry Letters, 1998, 8, 183-188.	2.2	23
248	Synthesis and evaluation of analgesic, antiinflammatory and antiplatelet properties of new 2-pyridylarylhydrazone derivatives. European Journal of Medicinal Chemistry, 1998, 33, 189-199.	5.5	188
249	Synthesis and antinociceptive properties of new structurally planned imidazo[1,2-a]pyridine 3-acylarylhydrazone derivatives. European Journal of Medicinal Chemistry, 1998, 33, 225-235.	5.5	61
250	Synthesis of New Benzylic Ethers of Oximes Derived from 1-Phenyl-pyrazole Compounds. Synthetic Communications, 1998, 28, 1299-1321.	2.1	6
251	Studies on Diastereoselective Synthesis of 3-Vinyl-5-carbomethoxy-2-oxabicyclo[3.3.0]octane Derivatives Employing Palladium(II) Oxidative Cyclization. Heterocycles, 1998, 48, 2621.	0.7	8
252	Synthesis of new 1,2-Benzothiazin-3-one Derivatives Designed as Dual Cyclooxygenase-2 and 5-Lipooxygenase Inhibitors. Journal of the Brazilian Chemical Society, 1998, 9, 119-130.	0.6	7

#	Article	IF	Citations
253	Reduction of 2-Alkyl-2-carbomethoxy-cyclopentanone Derivatives with Sodium Borohydride. II. The Elucidation of the Diastereoselective Control^a. Synthetic Communications, 1997, 27, 3241-3257.	2.1	18
254	Modelagem Molecular: Uma Ferramenta para o Planejamento Racional de FÃ¡rmacos em QuÃmica Medicinal. Quimica Nova, 1997, 20, 300-310.	0.3	18
255	SubstÃ¢ncias enantiomericamente puras (SEP): a questÃ£o dos fÃ¡rmacos quirais. Quimica Nova, 1997, 20, 647-656.	0.3	7
256	The synthesis of new isochromanylacetylarylhydrazones designed as probable non-addictive analgesic agents. Journal of the Brazilian Chemical Society, 1997, 8, 471-478.	0.6	8
257	SÃntese de Î²-cetoÃ©steres cÃclicos: novo procedimento para ciclizaÃ§Ã£o de Dieckmann empregando ALCL3 e trietilamina. Quimica Nova, 1997, 20, 435-437.	0.3	4
258	Improvement of enantioselective syntheses and chiral high resolution gas chromatographic analyses of (+)-2-allyl-2-carboethoxy-cyclopentanol. , 1997, 9, 321-324.		10
259	Design and Synthesis of a New 4-Oxa-8.OMEGA.-11-deoxy-5,6-dihydroprostacyclin Analogue.. Chemical and Pharmaceutical Bulletin, 1996, 44, 2157-2161.	1.3	11
260	Synthesis of condensed tricyclic pyrazolo[3,4-b]thieno[2,3-d]pyridine and related isostere derivatives. Journal of Heterocyclic Chemistry, 1996, 33, 309-313.	2.6	8
261	Synthesis and analgesic properties of new 4-arylhydrazone 1-H pyrazole [3,4-b] pyridine derivatives. Pharmaceutica Acta Helvetiae, 1996, 71, 213-219.	1.2	39
262	Crystal structure of pyrazole derivatives. IV. 5-chloro-4-chlorosulfonyl-3-methyl-1-phenylpyrazole. Journal of Chemical Crystallography, 1996, 26, 759-762.	1.1	1
263	Enantiofacial selective reduction of 2-allyl-2-carboethoxy-cyclopentanone mediated by baker's yeast. , 1996, 8, 305-310.		17
264	Molecular modeling on platelet-activating factor (PAF) and new proposed PAF antagonists. International Journal of Quantum Chemistry, 1996, 60, 1069-1080.	2.0	5
265	A semiempirical study of pyrazole acylhydrazones as potential antimalarial agents. International Journal of Quantum Chemistry, 1996, 60, 1835-1843.	2.0	8
266	Synthesis and Anti-Platelet Evaluation of New Tricyclic PAF Antagonists, Designed as Structurally Related to Hetrazepine Class - Web 2086. Journal of the Brazilian Chemical Society, 1996, 7, 247-256.	0.6	7
267	Design of new potential 5-lipoxygenase inhibitors, dual thromboxane synthase inhibitors, and thromboxane a2 receptor antagonists byAM1. International Journal of Quantum Chemistry, 1995, 56, 181-190.	2.0	5
268	The synthesis and analgesic properties of new spiroisochromanyl acid derivatives synthesized from natural safrole. Journal of Heterocyclic Chemistry, 1995, 32, 959-962.	2.6	9
269	Semiempirical calculations on the mechanism of stereoselective NaBH4 reduction of 2-methoxycarbonyl-2-allyl-cyclopentanone. Computational and Theoretical Chemistry, 1995, 340, 193-199.	1.5	3
270	Studies Toward the Diastereoselective Reduction of 2-Alkoxycarbonyl-2-allyl-cyclopentanone Derivatives with Boron Hydrides. Synthetic Communications, 1995, 25, 1133-1144.	2.1	22

#	Article	IF	Citations
271	Synthesis and analgesic properties of 5-acyl-arylhydrazone 1-H pyrazolo [3,4-b] pyridine derivatives. Pharmaceutica Acta Helvetiae, 1994, 69, 163-169.	1.2	40
272	The Synthesis and Antiinflammatory Activity of 1-Alkyl-Isochroman-1-yl Acetic Acids Derivatives. Journal of the Brazilian Chemical Society, 1993, 4, 40-44.	0.6	9
273	Synthesis of pyrazole derivatives as potential bioisosteres of thromboxaneâ€synthetase inhibitors. Journal of Heterocyclic Chemistry, 1992, 29, 407-411.	2.6	9
274	The synthesis of a new benzothiazine derivative, related to oxicams, synthesized from natural safrole. Journal of Heterocyclic Chemistry, 1992, 29, 1667-1669.	2.6	16
275	The Synthesis and Anti-inflammatory Properties of a New Sulindac Analogue Synthesized from Natural Safrole. Journal of Pharmaceutical Sciences, 1992, 81, 1219-1222.	3.3	20
276	The synthesis of a new 8â€azaprostanoid. Journal of Heterocyclic Chemistry, 1989, 26, 725-728.	2.6	6
277	Expeditious, stereocontrolled syntheses of racemic and natural brasilenol through intramolecular asymmetry transfer. Absolute stereochemistry of brasilenol. Journal of Organic Chemistry, 1987, 52, 1169-1170.	3.2	25
278	Selective synthesis of brasilenol, a novel sesquiterpene from the sea hare Aplysia brasiliana and the red alga Laurencia obtusa. Journal of Organic Chemistry, 1986, 51, 4250-4253.	3.2	13